A privately held biopharmaceutical company based in Tokyo, Japan, Anaeropharma Science was established in 2004 to pioneer the development of novel therapeutics to target such a hypoxic environment in solid cancers based on its proprietary platform technology, recombinant bifidobacterium therapeutics. » Read full article
Latest News
Introduced on Shinano Mainichi Shinbun
January 27th, 2012
Anaeropharma’s technology was introduced on Shinano Mainich Shinbun. December 31, 2011
We have moved to our new office
April 26th, 2011
See here for detail.
Fundraising of 700 million yen – capital contribution by INCJ
November 25th, 2010
Anaeropharma has successfully completed closing of 700 million yen financing for its clinical trials. The investor – Innovation Network Corporation of Japan (INCJ) plans to continuously contribute to Anaeropharma’s future potential financing.
Tie-up with Eisai Co., Ltd.
October 1st, 2010
Anaeropharma Science, Inc. and Eisai Co., Ltd. have concluded an option agreement concerning APS001, a novel anticancer agent currently under development at Anaeropharma Science that utilizes characteristic features of Bifidobacterium longum, as well as an agreement concerning the discovery of novel anticancer agents that utilize Bifidobacterium as a drug delivery system.
Introduced on Nikkei Business Daily
January 8th, 2010
Anaeropharma’s Technology was introduced on Nikkei Business Daily. November 30, 2009
Interviewed by Venture Valuation AG
August 6th, 2009
Anaeropharma CEO is interviewed by Venture Valuation, a Swiss information providing firm in the emerging industries.
Read more to visit Venture Valuation’s website.
JST grant
July 31st, 2008
Subscribe RSS